中望軟件(688083.SH):首次回購3萬股
格隆匯7月31日丨中望軟件(688083.SH)公佈,2024年7月31日,公司通過上海證券交易所交易系統以集中競價交易方式首次回購公司股份3萬股,佔公司目前總股本121,303,799股的比例為0.025%,回購成交的最高價為64.99元/股,最低價為61.48元/股,支付的資金總額為人民幣1,922,598.74元(不含印花税、交易佣金等交易費用)。因公司曾多次執行股份回購計劃,並將部分回購股份用於股權激勵或員工持股計劃。本次回購前,公司回購專用證券賬户存放公司股份433,901股;本次回購後,公司回購專用證券賬户存放股份增加至464,031股,佔公司總股本的比例為0.383%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.